News

Vertex Pharmaceuticals’ stock dipped 1.73%, underperforming the S&P 500’s mild loss, despite solid monthly gains. Investors ...
In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.73% at $464.20. The stock trailed the S&P 500, which registered a daily loss of 0.4%. At the same time, the Dow lost 0.98%, and ...
Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
Penserra Capital Management significantly reduced its stake in Vertex Pharmaceuticals, dropping 81% of its shares in the ...
Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...
Trump’s “big beautiful” bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of ...
New stem cell therapy offers hope for type 1 diabetes, freeing patients from insulin. Learn why diverse clinical trial ...
The Boston Arts Academy Foundation closed its Building Our Future fundraising campaign, surpassing its $35 million goal, thanks to twin $1 million donations – one from Vertex Pharmaceuticals ...